Dr. Jacob Daniels is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His background includes pharmacology, neurodegenerative diseases, small molecule drug discovery, cellular and molecular biology, and neuroscience. Jacob applies his experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Jacob completed his doctorate degree at Columbia University where his dissertation research in the laboratory of Professor Brent Stockwell focused on evaluating small molecule ferroptosis inhibitors for neurodegenerative disease applications.
Dr. Jacob Daniels is a patent agent in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His background includes pharmacology, neurodegenerative diseases, small molecule drug discovery, cellular and molecular biology, and neuroscience. Jacob applies his experience to patent prosecution, freedom-to-operate, and due diligence matters for clients in the life sciences, pharmaceutical, biotechnology, diagnostics, and medical devices industries.
Prior to joining the firm, Jacob completed his doctorate degree at Columbia University where his dissertation research in the laboratory of Professor Brent Stockwell focused on evaluating small molecule ferroptosis inhibitors for neurodegenerative disease applications.
- Ph.D., Pharmacology and Molecular Signaling, Columbia University, 2022
Predoctoral Fellow in Pharmacology and Toxicology, PhRMA Foundation
- M.Phil., Pharmacology and Molecular Signaling, Columbia University, 2019
- M.A., Pharmacology and Molecular Signaling, Columbia University, 2017
- B.S., Double Major in Chemistry and Neuroscience, The College of William and Mary, 2015
- U.S. Patent and Trademark Office
- Ph.D., Pharmacology and Molecular Signaling, Columbia University, 2022
Predoctoral Fellow in Pharmacology and Toxicology, PhRMA Foundation
- M.Phil., Pharmacology and Molecular Signaling, Columbia University, 2019
- M.A., Pharmacology and Molecular Signaling, Columbia University, 2017
- B.S., Double Major in Chemistry and Neuroscience, The College of William and Mary, 2015
- U.S. Patent and Trademark Office
Select Publications
- Co-author with H.Liu, S. Iketani, et al., “Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19,” 13(1): 1891 Nature Communications, 2022
- Co-author with V.A.N. Kraft, C.T. Bezjian, et al., “GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling,” 6(1) ACS Central Science 41-53, 2020
- Co-author with Y. Zhang, H. Tan, et al., “Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model,” 26(5) Cell Chemical Biology 623-633, 2019
- Co-author with M.M. Gaschler, A.A. Andia, et al., “FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation,” 14(5) Nature Chemical Biology 507-515, 2018
Select Publications
- Co-author with H.Liu, S. Iketani, et al., “Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19,” 13(1): 1891 Nature Communications, 2022
- Co-author with V.A.N. Kraft, C.T. Bezjian, et al., “GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling,” 6(1) ACS Central Science 41-53, 2020
- Co-author with Y. Zhang, H. Tan, et al., “Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model,” 26(5) Cell Chemical Biology 623-633, 2019
- Co-author with M.M. Gaschler, A.A. Andia, et al., “FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation,” 14(5) Nature Chemical Biology 507-515, 2018
- Privacy Policy
- Terms of Use
- Accessibility